%0 Journal Article
%T SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation
%A Jetske Ruiterkamp
%A Adri C Voogd
%A Vivianne CG Tjan-Heijnen
%A Koop Bosscha
%A Yvette M van der Linden
%A Emiel Rutgers
%A Epie Boven
%A Maurice JC van der Sangen
%A Miranda F Ernst
%A In collaboration with Dutch Breast Cancer Trialists' Group (BOOG)
%J BMC Surgery
%D 2012
%I BioMed Central
%R 10.1186/1471-2482-12-5
%X Randomization will take place after the diagnosis of primary distant metastatic breast cancer. Patients will either be randomized to up front surgery of the breast tumor followed by systemic therapy or to systemic therapy, followed by delayed local treatment of the breast tumor if clinically indicated.Patients with primary distant metastatic breast cancer, with no prior treatment of the breast cancer, who are 18 years or older and fit enough to undergo surgery and systemic therapy are eligible. Important exclusion criteria are: prior invasive breast cancer, surgical treatment or radiotherapy of this breast tumor before randomization, irresectable T4 tumor and synchronous bilateral breast cancer. The primary endpoint is 2-year survival. Quality of life and local tumor control are among the secondary endpoints.Based on the results of prior research it was calculated that 258 patients are needed in each treatment arm, assuming a power of 80%. Total accrual time is expected to take 60 months. An interim analysis will be performed to assess any clinically significant safety concerns and to determine whether there is evidence that up front surgery is clinically or statistically inferior to systemic therapy with respect to the primary endpoint.The SUBMIT study is a randomized controlled trial that will provide evidence on whether or not surgery of the primary tumor in breast cancer patients with metastatic disease at initial presentation results in an improved survival.NCT01392586.In most western countries, around five percent of all patients with breast cancer have distant metastatic disease at initial presentation [1,2]. This accounts for 500 newly diagnosed patients each year in the Netherlands [1]. Because metastatic breast cancer is considered to be an incurable disease, the aim of the treatment for these patients is to provide palliation amongst others with systemic therapy. Usually, breast surgery is restricted to those patients in whom the breast tumor is symptomat
%K Primary metastatic breast cancer
%K surgery
%K randomised controlled trial
%U http://www.biomedcentral.com/1471-2482/12/5